RetCAD is cleared for clinical use in New Zealand

Our RetCAD solution is cleared for clinical use in New Zealand. We look forward to working with our users in New Zealand on the analysis of their retinal images.

Structural Insights in Severe Asthma Paving the Way for More Precise Treatment Stratification

Redefining Bronchiectasis Trials Through AI-Powered Image Analysis

Thirona Receives FDA Clearance for LungQ® 4 Software, Expanding AI-Powered Capabilities in Lung Image Analysis for the U.S. Market

Thirona and VIDA Diagnostics Partner to Accelerate Respiratory Clinical Trials with Advanced AI Imaging

Comprehensive assessment of mucus impaction with Artificial Intelligence

Artificial Intelligence detects substantial airway damage on CT scans of children with severe asthma

Do you want to stay up to date with our new developments?

RetCAD is cleared for clinical use in New Zealand

Structural Insights in Severe Asthma Paving the Way for More Precise Treatment Stratification

Redefining Bronchiectasis Trials Through AI-Powered Image Analysis

Thirona Receives FDA Clearance for LungQ® 4 Software, Expanding AI-Powered Capabilities in Lung Image Analysis for the U.S. Market

Thirona and VIDA Diagnostics Partner to Accelerate Respiratory Clinical Trials with Advanced AI Imaging

Comprehensive assessment of mucus impaction with Artificial Intelligence

Artificial Intelligence detects substantial airway damage on CT scans of children with severe asthma

Do you want to stay up to date with our new developments?

Sign up to receive product and technology updates.